MedTrace Logo

A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough

NCT02993822 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 315

Last updated 2022-04-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the effectiveness of three doses of orvepitant, taken once a day, in the treatment of chronic refractory cough.

Conditions

  • Chronic Refractory Cough

Interventions

DRUG

Orvepitant Maleate

Tablet, once daily, oral

DRUG

Placebo

Tablet, once daily, oral

Sponsors & Collaborators

  • Nerre Therapeutics Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-22
Primary Completion
2019-01-14
Completion
2019-01-24
FDA Drug
Yes

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02993822 on ClinicalTrials.gov